BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KESHO
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260409T190000
DTEND;TZID=Africa/Nairobi:20260509T203000
DTSTAMP:20260527T173749
CREATED:20260526T192731Z
LAST-MODIFIED:20260526T193025Z
UID:41708-1775761200-1778358600@kesho-kenya.org
SUMMARY:The Role of Multimodal Treatment in Esophageal Cancer
DESCRIPTION:Moderator: Dr. Omar Abdihamid\nSpeakers: Dr. Juma Odoro\, Dr. Rogers Mongare\, Dr. Kevin Makori\nDate: 9 April 2026\n\nThis session examined esophageal cancer management through a multidisciplinary lens\, bringing together surgical\, radiotherapeutic and systemic treatment perspectives across the continuum of care. \nA central theme was that treatment selection depends on accurate staging\, patient fitness\, disease burden and early alignment between disciplines. In many African settings\, patients may present with locally advanced disease and nutritional compromise\, making timely diagnosis\, staging and supportive care central to outcomes. \nThe surgical discussion focused on the role of resection in appropriately selected patients\, where careful assessment of resectability\, operative risk\, nodal disease and perioperative optimisation shape whether surgery can offer curative benefit. The session also reinforced that surgery is rarely a standalone decision; it must be integrated with oncology input and long-term follow-up. \nRadiotherapy was addressed as part of multimodal care\, with roles in neoadjuvant\, definitive\, adjuvant and palliative pathways depending on stage and patient factors. The discussion highlighted the need for precise planning\, symptom control and realistic treatment pathways that reflect available infrastructure and patient access. \nIn metastatic disease\, systemic therapy remains central\, with evolving use of combination approaches\, targeted treatment and biomarker-directed strategies. However\, implementation must be balanced with access\, cost\, toxicity\, performance status and local service realities. \nAcross the session\, a consistent message emerged: esophageal cancer care requires deliberate sequencing—matching the right treatment to the right patient at the right point in the disease course. \nKey Takeaways\n\nEsophageal cancer management depends on accurate staging\, nutrition assessment and multidisciplinary planning.\nSurgery remains important in resectable disease but requires careful patient selection and perioperative optimisation.\nRadiotherapy has curative\, consolidative and palliative roles within multimodal treatment.\nMetastatic disease management is evolving with systemic combinations and biomarker-driven options.\nAccess\, treatment tolerance and supportive care shape real-world implementation in Kenya and the wider region.\nEarly referral and MDT decision-making are critical to improving outcomes.
URL:https://kesho-kenya.org/event/the-role-of-multimodal-treatment-in-esophageal-cancer/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2026/05/The-Role-of-Multimodal-Treatment-in-Esophageal-Cancer-e1779823765248.png
END:VEVENT
END:VCALENDAR